Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
347
resultados
Última actualización
27/07/2026 [09:40:00]
Resultados 275 a 300 de 347
Resumen de: US20260151513A1
0000 Compositions and methods for the treatment of leukodystrophy, particularly, H-ABC are disclosed.
Resumen de: US20260153520A1
0000 The present invention relates to a method of detecting one or more tissue-derived aggregated proteins in a biological sample.
Resumen de: US20260152551A1
0000 The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Resumen de: US20260152566A1
0000 Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Resumen de: US20260151494A1
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: WO2026116669A1
The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.
Resumen de: KR20260081349A
0001a 본 발명은 타겟 물질에 결합할 수 있는 캡쳐 및 상기 캡쳐 상에 결합된 캡쳐 프로프가 고정된 용기에 타겟 물질을 포함하는 시료를 가하여, 상기 캡쳐에 타겟 물질을 결합시키는 단계; 상기 용기를 세척하여, 시료 중 상기 캡쳐에 결합하지 않은 물질을 제거하는 단계; 상기 용기에 상기 캡쳐 프로브에 결합하는 검출 프로브를 가하여, 상기 검출 프로브 중 적어도 일부를 상기 캡쳐 프로브에 결합시키는 단계; 및 상기 용기내 전극에 상기 캡쳐 프로브에 결합하지 않은 검출 프로브를 결합시켜, 결합 전 후의 전기적 신호 변화를 측정하는 단계;를 포함함으로써, 빠르고 간편한 방법으로 시료내 타겟 물질의 존부를 확인하고, 그 양을 정량화할 수 있도록 하는 타겟 물질의 검출 방법에 관한 것이다.
Resumen de: WO2026115269A1
The present invention provides a method for detecting an analyte in a sample, the method comprising steps (i)-(iv). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region having an absence of the optical component. It is the set of local regions of the optical component having an absence of the optical component that are detected.
Resumen de: WO2026117508A1
The present disclosure provides methods of predicting/diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.
Resumen de: WO2024239122A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: AU2024378628A1
It has proven difficult to automate the detection of neurodegenerative disorders in patients. Thus, detection is currently still performed via visual inspection. Accordingly, embodiments automate the detection of neurodegenerative disorders by deriving sleep biomarker(s) from physiological data, acquired while a subject is sleeping, and applying a classifier to the sleep biomarker(s) to output a risk probability for each neurodegenerative disorder. Embodiments also characterize the neurodegenerative disorder(s) by assigning a risk severity based on the risk probability(ies), output by the classifier.
Resumen de: EP4752856A1
0001 The present invention relates to the field of medical diagnosis, and more particularly to methods for detecting the risk of having mental health-related diseases by means of analyzing morphological changes in specific immune cells of the central nervous system, such as microglia, using convolutional neural network-based artificial intelligence.
Resumen de: EP4752550A2
0001 Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Resumen de: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Resumen de: EP4752155A1
The present invention relates to genetically encoded cellular iron biosensors, in particular to nucleic acids encoding the same, vectors and cells comprising the nucleic acid(s), in vitro methods for measuring, and optionally monitoring, cellular Fe2+ and/or cellular iron-sulfur cluster (ISC), in vitro screening methods for a compound that affects cellular Fe2+ and/or cellular ISC, and to in vitro methods for identifying a dosage and/or formulation of a compound that affects cellular Fe2+ and/or cellular ISC.
Resumen de: CN122130960A
本申请涉及医疗器械领域，具体涉及应用于脑神经科学领域和临床医学领域，涉及诊断或辅助诊断阿尔茨海默病的标志物组合，特别涉及Aβ1‑42、Aβ1‑40和p‑Tau217的组合，尤其是经由Aβ1‑42、Aβ1‑40和p‑Tau217获得的比值p‑Tau217/(Aβ1‑42/Aβ1‑40)。比值p‑Tau217/(Aβ1‑42/Aβ1‑40)受样本保存条件的影响小，更稳定，有助于排除样本保存过程中抗原，例如Aβ1‑42、Aβ1‑40、p‑Tau217不稳定对疾病诊断的影响。
Resumen de: WO2024211475A1
Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
Resumen de: CN122130941A
本发明涉及一种基于卟啉共价有机框架@聚吲哚五甲醛的光阳极材料及其制备方法和应用，属于光电化学生物传感器技术领域。本发明采用Dha与Tph通过溶剂热法合成D‑T‑COF，并将其修饰于FTO导电基底表面；进一步通过电聚合法沉积P5FIn，在D‑T‑COF表面形成均匀且广域分布的p‑n异质结结构。基于D‑T‑COF@P5FIn复合材料与p‑tau217捕获抗体，构建了可精准识别人血浆中痕量p‑tau217的光电化学免疫传感器阵列，其在灵敏度、特异性和实用性方面均实现显著突破，尤其适用于复杂生物基质中极低浓度标志物的可靠检测，在临床转化应用中展现出广阔前景。
Resumen de: CN122130945A
0001 本发明涉及一种外周血中性粒细胞分子分型试剂盒及其在肺癌早诊的应用，属于肿瘤技术领域。本发明试剂盒包括靶序列的杂交探针和荧光报告探针；所述靶序列杂交探针的核苷酸序列如SEQ ID NO：11‑25所示；所述荧光报告探针核苷酸序列如SEQ ID NO：26所示。本发明将靶序列的杂交探针的序列设计成一部分与靶基因杂交，另一部分与荧光报告探针杂交，通过荧光报告探针的荧光值可以鉴定或区分靶细胞。通过本发明试剂盒可将中性粒细胞鉴定或划分为CXCL8、LYZ、IL1R2、S100A12、IFI16基因阳性表达的中性粒细胞亚群。这些基因阳性表达的中性粒细胞亚群可以用于诊断早期癌症。
Resumen de: CN122127439A
本发明涉及一种新型载脂蛋白E突变截短体及其校准品、质控品的制备方法。载脂蛋白E突变截短体，其氨基酸序列如SEQ ID所示；载脂蛋白E突变截短体检测的校准品、质控品稀释液包括防腐剂、蛋白保护组合物、表面活性剂组合物、离子稳定剂组合物、缓冲液；载脂蛋白E突变体的制备方法，包括如下几点：1，确定突变截短体的具体序列；2，确定突变位点位于野生型载脂蛋白E的78位点；3，含NdeI位点及突变序列；锁定突变；结合大肠杆菌对载脂蛋白E核苷酸进行人工优化；4，通过电泳截取相应的突变的截短体；5，经过大肠杆菌重组，得到载脂蛋白E突变截短体。本发明解决了检测结果与实际临床不符以及载脂蛋白E校准品稳定性差等问题。
Resumen de: WO2022243435A1
The present invention relates to i) KL1333 for use in the treatment of mitochondrial diseases or diseases associated with mitochodrial diseases such as fatigue such as fatigue syndrome and fatigue associated with a disease or muscle weakness associated with a mitochondrial disease, ii) KL1333 for use in a dosage regime for the treatment of one or more of fatigue, muscle weakness or a mitochondrial disease, iii) use of blood lactate (mM)Zpyruvate (mM) ratio as biomarker of KL1333 treatment effect, wherein a decrease in ratio indicates that the treatment is effective, and iv) use of serum niacinamide and/or xanthine as biomarker of KL1333 treatment effect, wherein an increase in the ratio of niacinamide and/or xanthine concentrations indicates that the treatment is effective and the ratio of niacinamide and/or xanthine concentrations is (serum concentration at test day)/(serum concentration at the start of the treatment).
Resumen de: CN122124828A
0001 本发明公开了一种Ti<3>C<2>@MnO<2>异质结构材料及制备方法和应用，本发明以Ti<3>AlC<2>、LiF和HCl为前驱体，通过弱酸刻蚀法将前驱体Ti<3>AlC<2>中的Al原子剥离制备了Ti<3>C<2>，并以Ti<3>C<2>为基质，以高锰酸钾为锰源，采用微波法制备了Ti<3>C<2>@MnO<2>异质结构材料，制备的Ti<3>C<2>@MnO<2>异质结构材料具有催化性能好、电子传输能力强和物化性能稳定的特征。本发明还基于Ti<3>C<2>@MnO<2>异质结构材料具有类氧化酶活性和光电催化活性的性能，构建了比色和光电传感器用于GSH的检测，具有优良的抗干扰能力和高选择性的优点。该传感器具有双重信号的测定功能，可以增加测量的动态范围，并为环境和浓度因素提供内置校正，解决了传感器背景信号干扰大、灵敏度低的问题。
Resumen de: WO2024263939A1
The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.
Nº publicación: CN122139125A 02/06/2026
Solicitante:
爱丁堡大学理事会
Resumen de: WO2018007817A1
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.
BOPI
Sede Electrónica
